Asia Green Biotechnology

Asia Green Biotechnology FCF Yield

Delisted·Sep 23, 2026

The Free Cash Flow Yield of Asia Green Biotechnology (ASIA.CN) as of Nov 15, 2026 is -6.56 %. In the previous year, Free Cash Flow Yield was -23.61 % — a change of -72.21% (higher).

FCF Yield

-6.56 %

YoY

-72.21%

Last updated:

Free Cash Flow Yield of Asia Green Biotechnology is 2023 -6.56 % . Free Cash Flow Yield of Asia Green Biotechnology was 2022 -23.61 % . It decreases by -72.21% higher compared to the previous year.

The Asia Green Biotechnology FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-14.80 CAD
Jan 1, 2019
-121.94 CAD
Jan 1, 2020
-116.51 CAD
Jan 1, 2021
-84.34 CAD
Jan 1, 2022
-23.61 CAD
Jan 1, 2023
-6.56 CAD
The Asia Green Biotechnology FCF Yield history
YEARFCF YieldYoY
-6.56 %-72.21%
-23.61 %-72.00%
-84.34 %-27.61%
-116.51 %-4.46%
-121.94 %+724.06%
-14.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Asia Green Biotechnology Stock analysis

What does Asia Green Biotechnology do? Asia Green Biotechnology Corp develops and supplies proprietary organic hybridization technology for agri-technology applications. The company partners with InPlanta Biotechnology Inc. for hemp cultivation under a license agreement, and collaborates with Swysh Inc. and Pathway Rx Corp for cannabinoid extract development. Revenue is generated through the supply of technology and related products, with operations expanding in Cambodia and Thailand through R&D programs. The firm focuses on commercial hemp and cannabinoid product development under licensed agreements. The company's primary market segments include agricultural technology providers and medicinal cannabinoid extract buyers. InPlanta Biotechnology Inc. licenses hemp cultivation, while Swysh Inc. and Pathway Rx Corp. license cannabinoid extract development. Asia Green Biotechnology Corp. supplies technology and manages the commercialization of these products derived from its organic hybridization technology. Asia Green Biotechnology Corp. operates under license agreements with InPlanta Biotechnology Inc., Swysh Inc., and Pathway Rx Corp. to develop and supply hemp and cannabinoid products. The company's revenue streams come from technology supply and product commercialization under these agreements, with R&D programs in Cambodia and Thailand supporting future market expansion. Asia Green Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Asia Green Biotechnology stock

Free Cash Flow Yield of Asia Green Biotechnology is -6.56 % in 2023.

Free Cash Flow Yield of Asia Green Biotechnology changed from -23.61 % to -6.56 %, representing a -72.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Asia Green Biotechnology since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Asia Green Biotechnology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Asia Green Biotechnology

All Key Metrics — Asia Green Biotechnology